Ceftazidime

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Ceftazidime is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 3 molecular targets, including mrcA, ftsI and mrcB. Recorded indications include Bacterial infection due to Klebsiella pneumoniae, Bacterial meningitis, Bacterial pneumonia and Bacterial septicemia.

• Approval status: ofp (first approved 1985 by the FDA).
• Molecular targets: mrcA, ftsI and mrcB (3 listed in DrugCentral).
• Indications: Bacterial infection due to Klebsiella pneumoniae, Bacterial meningitis, Bacterial pneumonia, Bacterial septicemia and Bacterial urinary infection and others.
• ATC code: J01DD02 (Third-generation cephalosporins).
• Molecular formula: C22H23N6O7S2; molecular weight 547.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (63)

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial meningitis
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Citrobacter Pneumonia
• Complicated Proteus UTI
• Complicated UTI with Pseudomonas Aeruginosa
• E. Coli Cervicitis
• E. Coli Endometritis
• E. Coli Gynecological Infections
• E. Coli Pelvic Cellulitis
• E. Coli Pelvic Inflammatory Disease
• E. Coli Peritonitis
• Ecthyma gangrenosum
• Endometritis
• Enterobacter Osteomyelitis
• Enterobacter Pneumonia
• EnterobacterJoint Infection
• Escherichia coli urinary tract infection
• Gonococcal meningitis
• H. Influenzae Meningitis
• Haemophilus influenzae pneumonia
• Haemophilus Septicemia
• Infection due to Enterobacteriaceae
• Infection due to Escherichia coli
• Infection due to Staphylococcus aureus
• Infection of bone
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• + 33 more

Off-label uses (7)

• Diabetic Foot Infection
• Infection by Yersinia enterocolitica
• Melioidosis
• Pseudomonas Respiratory Tract Infection in Cystic Fibrosis
• Pseudotuberculosis
• Pyrexia of unknown origin
• Ventilator-acquired pneumonia

Contraindications (5)

• Blood coagulation disorder
• Disease of liver
• Factor II deficiency
• Kidney disease
• Pseudomembranous enterocolitis

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Penicillin-binding protein 1A	mrcA	inhibitor	IC50 6.53
Peptidoglycan synthase FtsI	ftsI	inhibitor	IC50 6.26
Penicillin-binding protein 1B	mrcB	inhibitor	IC50 4.96

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-07-19	FDA	—	COVIS INJECTABLES

ATC classification

ATC code	Therapeutic hierarchy
J01DD02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
J01DD52	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Aplastic anaemia	603.0
Septic shock	373.2
Pathogen resistance	352.3
Multiple organ dysfunction syndrome	292.8
Choroiditis	286.0
Drug resistance	264.2
Hyperbilirubinaemia	241.2
Drug reaction with eosinophilia and systemic symptoms	235.0
Endophthalmitis	228.1
Mucosal inflammation	222.6
Pseudomonas infection	212.8
Toxic epidermal necrolysis	212.6

Chemical structure

• Molecular formula: C₂₂H₂₃N₆O₇S₂
• Molecular weight: 547.58 g/mol
• CAS number: 72558-82-8
• InChIKey: ORFOPKXBNMVMKC-DWVKKRMSSA-O
• PubChem CID: 5481173

CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ceftazidime used for?

DrugCentral lists the following indications for Ceftazidime: Bacterial infection due to Klebsiella pneumoniae, Bacterial meningitis, Bacterial pneumonia, Bacterial septicemia, Bacterial urinary infection, Citrobacter Pneumonia, Complicated Proteus UTI and Complicated UTI with Pseudomonas Aeruginosa and others.

How does Ceftazidime work?

Its molecular targets in DrugCentral include mrcA (inhibitor), ftsI (inhibitor) and mrcB (inhibitor).

When was Ceftazidime first approved?

Ceftazidime was first approved by the FDA in 1985.

What is the chemical formula of Ceftazidime?

Ceftazidime has the molecular formula C22H23N6O7S2 and a molecular weight of 547.58 g/mol.

Sources

• DrugCentral drug card 559 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200768 — compound record and bioactivity
• PubChem CID 5481173 — chemical identifiers
• DrugBank DB00438 — drug record
• FDA UNII 9M416Z9QNR — substance identity
• DailyMed: FDA labels for Ceftazidime — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.